PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025New England Journal of Medicine77 citations

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

View Full Paper
LCLuciano J. CostaNBNizar J. BahlisAPAurore Perrot

Key Points

  • The goal was to compare the efficacy of teclistamab plus daratumumab in multiple myeloma patients.
  • Patients received teclistamab plus daratumumab regimen compared to DPd or DVd groups.
  • Participants had one to three previous lines of therapy.
  • The teclistamab-daratumumab group had significantly longer progression-free survival than those in DPd or DVd group.

Abstract

In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson ClinicalTrials.gov number, NCT05083169.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Costa et al. (2025) studied this question.

synapsesocial.com/papers/69401d682d562116f28f900chttps://doi.org/10.1056/nejmoa2514663
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)2024 · 3 citations
  2. 2Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting2024 · 3 citations
  3. 3Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma2020 · 126 citations
  4. 4P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE2022 · 10 citations
  5. 5Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 12011 · 1,042 citations